Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Patient centricity at Astellas—all about action

11/30/2021 | 01:21am EST

"At the end of any discussion on patient centricity, you tend to get to a, 'why' or 'so what?' That's a great topic, but what's meaningful about it?" These are questions that Anthony Yanni, a primary care physician, MBA, Astellas' Senior Vice President and Global Head of Patient Centricity has heard often. Discussions on advancing patient-centric cultures abound across the industry but turning talk into meaningful action is essential to effect real change for companies and the patients they serve.

For Astellas, patient centricity is not about buzzwords and grand statements; it is about action. It is about robust practices and a fundamental understanding of real-world settings. It involves crafting processes and capabilities that enable Astellas to deliver. It is about reaching a stage where the voices of both patients and researchers are equally represented during the drug development process.

Astellas' patient centricity vision-to support the development of innovative health solutions through a deep understanding of the patient experience, medical needs, and behavioral drivers of care-is not just a convenient statement. It is a guiding principle for action, which supports the company's corporate strategy.

Disclaimer

Astellas Pharma Inc. published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 06:20:11 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
01/20ASTELLAS PHARMA : We posted the presentation material for media briefing on Digital Transf..
PU
01/20ASTELLAS PHARMA : Digital Transformation of Astellas Pharma(3,351KB)
PU
01/19Essa Pharma Commences Dosing in Phase 1/2 Clinical Trial of Prostate Cancer Combo Thera..
MT
01/16Glenmark Pharmaceuticals Unit Gets US FDA's Approval for Regadenoson Injection
MT
01/10Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t..
AQ
01/10Modalis Therapeutics and Astellas Pharma End Research Collaboration on Nervous System M..
MT
01/07Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US
MT
01/07Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million..
DJ
01/07Modalis Announces Termination of Research Collaboration on MDL-204
CI
01/06Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration ..
AQ
More news
Financials
Sales 2022 1 334 B 11 728 M 11 728 M
Net income 2022 183 B 1 613 M 1 613 M
Net cash 2022 380 B 3 342 M 3 342 M
P/E ratio 2022 19,7x
Yield 2022 2,59%
Capitalization 3 583 B 31 486 M 31 505 M
EV / Sales 2022 2,40x
EV / Sales 2023 2,12x
Nbr of Employees 15 455
Free-Float -
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 933,50 JPY
Average target price 2 451,67 JPY
Spread / Average Target 26,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa Executive Officer
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.3.37%31 486
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356